Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Torpharm Ticlopidine Ad To Run In August JAMA; Educational Materials Cited

Executive Summary

Apotex' U.S. subsidiary Torpharm will run an advertisement in the August issue of the Journal of the American Medical Association referencing its safety education program for the first generic version of ticlopidine (Roche's Ticlid). Torpharm's ticlopidine cleared FDA July 1 with a therapeutically equivalent "AB" rating.

You may also be interested in...



Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program

Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.

Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program

Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.

Dismissal Of Teva Suit Triggered Ticlopidine 180-Days, Appeals Court Rules

Torpharm's 180-day ticlopidine exclusivity was triggered by the June 1998 dismissal of Teva's declaratory judgment action against Roche in California federal court, the D.C. federal appeals court ruled July 20.

Related Content

UsernamePublicRestriction

Register

PS034490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel